Vaccine protects against multiple fungal infections without hurting the gut

Researchers at the University of Georgia have developed a vaccine called NXT-2 that effectively protects against multiple life-threatening fungal infections in preclinical animal models, while maintaining the diversity of the gut microbiome, according to a new study published in Microbiology Spectrum. The vaccine, which targets pathogenic strains of Candida and Aspergillus, has been shown to be effective against the three most common fungal pathogens responsible for over 80% of fatal fungal infections.

The study is the first to evaluate the vaccine's impact on the naturally occurring fungal and bacterial communities in the gut, known as the microbiome. Karen Norris, the corresponding author of the study, emphasized the importance of confirming that the immune response provided by NXT-2 would not disrupt the balance of beneficial microbes in the gut.

The findings suggest that the vaccine provides protection against pathogenic fungi without significantly altering the resident fungal or bacterial populations in the gut. This research has significant implications, as fungal infections kill millions each year and cost billions in healthcare expenses. Current treatments are ineffective against drug-resistant fungal infections, and some antifungal drugs can alter the populations of nonharmful fungi and bacteria in the gut.

The study supports the development of a broadly protective fungal vaccine, crucial in the face of increasing fungal infection rates among the general population, particularly in immunocompromised individuals.